Article and Video CATEGORIES
Denise has over 30 years of varying experience in the healthcare arena. In August 2009 she joined The Global Resource for Advancing Cancer Education as one of its first employees. She has grown with the organization and now oversees the operational movement of programs, efficiency, and effectiveness within the organization, as well as the daily processes and functions.
Join us on SATURDAY, JULY 15th, 2023, for the 2023 Targeted Therapies Patient Forum
This virtual program is presented Live Online from 10 AM - 4 PM EDT
In this 9th annual live patient forum, leading thoracic oncologists from around the world as well as lung cancer patients who are active within the patient advocacy community discuss subjects relevant to all targets as well as breakout sessions on rare mutations.
This 6-hour live virtual webinar is an opportunity for lung cancer patients and caregivers to hear from experts and participate in live virtual Q&A sessions. The forum offers panel discussions, live Q&A sessions, and breakout sessions focused on rare mutations such as EGFR, ALK, ROS, RET and KRAS. This event is free but registration is required and limited. For more information visit the full AGENDA. Faculty Bio's willl be available soon.
2023 Targeted Therapies in Lung Cancer Patient Forum
***Subject to Change***
Event Chairs: Sandip Patel, MD, Jessica Lin, MD
Topics include:
- Biomarker Testing: The Fundamentals and The Challenges
- Non-Metastatic Disease and Targeted Therapies
- After or Adding To Targeted Therapy
- Patient and Research Advocacy Presentation
- Resistance Mechanisms and Re-Biopsies
- Symptom Management and Palliative Care
Breakout Session Rooms will include the following discussions:
- EGFR
- EGFR Ex 20, HER 2
- ALK, ROS 1
- RET, Rare Fusions
- KRAS
- MET, BRAF
Each session includes full Panel Discussions and Q&A Sessions. View the full AGENDA here.
Please feel free to offer comments and raise questions in our
discussion forums.
Related Content
Forum Discussions
Hi elysianfields and welcome to Grace. I'm sorry to hear about your father's progression.
Unfortunately, lepto remains a difficult area to treat. Recently FDA approved the combo Lazertinib and Amivantamab...
Hello Janine, thank you for your reply.
Do you happen to know whether it's common practice or if it's worth taking lazertinib without amivantamab? From all the articles I've come across...
Hi elysianfields,
That's not a question we can answer. It depends on the individual's health. I've linked the study comparing intravenous vs. IV infusions of the doublet lazertinib and amivantamab...
Recent Comments
That's…